 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
AVANIR PHARMACEUT, (AVN) Stock Rating Learn More
| Our Overall Rating on AVANIR PHARMACEUT, AVN is Not Available | | AVANIR Pharmaceuticals engages in the discovery and development of drugs for the treatment of chronic diseases. The company develops Neurodex for the treatment of pseudobulbar affect and for the treatment of chronic diabetic neuropathic pain. It also develops a product for allergy and asthma, AVP-13358, which is in Phase I clinical development. In addition, AVANIR engages in research and development of other drugs that are in various phases of clinical and preclinical development, which include treatments of neuropathic pain, inflammation, and atherosclerosis. The company also conducts research in developing human antibody products for infectious diseases. Its product, docosanol 10 ream, is sold as an over-the-counter treatment for cold sores in North America. The company, using its XenerexTM technology, conducts research to develop injectable human monoclonal antibody products for anthrax, cytomegalovirus, and other infectious diseases. AVANIR was formed in 1988 and is based in San Diego, California. | | Our Not Available Rating on AVN was issued on 11/22/2008 |
AVANIR PHARMACEUT Technical Rating
|
|
|
|
